⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLDX News
Celldex Therapeutics, Inc
Celldex to Present at Upcoming Investor Conferences
globenewswire.com
CLDX
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
globenewswire.com
CLDX
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients
globenewswire.com
CLDX
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
globenewswire.com
CLDX